Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
- Response deadline
- Nov 16, 2027 Due in 436 days
- Date posted
- Nov 18, 2024
- Source
- Open notice
Description
This Notice of Funding Opportunity (NOFO) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants will support innovative studies designed to investigate biological/genetic bases of cancer health disparities, such as (1) mechanistic studies of biological factors associated with cancer health disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This NOFO is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities.
Classifications
- NAICS93.393
Documents (1)
- DownloadPAR-25-244-Full-Announcement.htmltext/html422 B
Contacts
- grantsinfo@nih.gov301-402-2541
Similar contracts
- NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)Due Sep 18, 2026
- Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)Due Jul 5, 2029
- Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 eSubmission Clinical Trial Optional)Due Sep 7, 2028
- Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)Due Sep 10, 2027
- Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)Due Oct 8, 2027
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)Due Jan 7, 2027